Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study.


Journal

The lancet. Diabetes & endocrinology
ISSN: 2213-8595
Titre abrégé: Lancet Diabetes Endocrinol
Pays: England
ID NLM: 101618821

Informations de publication

Date de publication:
10 2020
Historique:
received: 17 05 2020
revised: 10 07 2020
accepted: 15 07 2020
pubmed: 18 8 2020
medline: 30 9 2020
entrez: 18 8 2020
Statut: ppublish

Résumé

Although diabetes has been associated with COVID-19-related mortality, the absolute and relative risks for type 1 and type 2 diabetes are unknown. We assessed the independent effects of diabetes status, by type, on in-hospital death in England in patients with COVID-19 during the period from March 1 to May 11, 2020. We did a whole-population study assessing risks of in-hospital death with COVID-19 between March 1 and May 11, 2020. We included all individuals registered with a general practice in England who were alive on Feb 16, 2020. We used multivariable logistic regression to examine the effect of diabetes status, by type, on in-hospital death with COVID-19, adjusting for demographic factors and cardiovascular comorbidities. Because of the absence of data on total numbers of people infected with COVID-19 during the observation period, we calculated mortality rates for the population as a whole, rather than the population who were infected. Of the 61 414 470 individuals who were alive and registered with a general practice on Feb 16, 2020, 263 830 (0·4%) had a recorded diagnosis of type 1 diabetes, 2 864 670 (4·7%) had a diagnosis of type 2 diabetes, 41 750 (0·1%) had other types of diabetes, and 58 244 220 (94·8%) had no diabetes. 23 698 in-hospital COVID-19-related deaths occurred during the study period. A third occurred in people with diabetes: 7434 (31·4%) in people with type 2 diabetes, 364 (1·5%) in those with type 1 diabetes, and 69 (0·3%) in people with other types of diabetes. Unadjusted mortality rates per 100 000 people over the 72-day period were 27 (95% CI 27-28) for those without diabetes, 138 (124-153) for those with type 1 diabetes, and 260 (254-265) for those with type 2 diabetes. Adjusted for age, sex, deprivation, ethnicity, and geographical region, compared with people without diabetes, the odds ratios (ORs) for in-hospital COVID-19-related death were 3·51 (95% CI 3·16-3·90) in people with type 1 diabetes and 2·03 (1·97-2·09) in people with type 2 diabetes. These effects were attenuated to ORs of 2·86 (2·58-3·18) for type 1 diabetes and 1·80 (1·75-1·86) for type 2 diabetes when also adjusted for previous hospital admissions with coronary heart disease, cerebrovascular disease, or heart failure. The results of this nationwide analysis in England show that type 1 and type 2 diabetes were both independently associated with a significant increased odds of in-hospital death with COVID-19. None.

Sections du résumé

BACKGROUND
Although diabetes has been associated with COVID-19-related mortality, the absolute and relative risks for type 1 and type 2 diabetes are unknown. We assessed the independent effects of diabetes status, by type, on in-hospital death in England in patients with COVID-19 during the period from March 1 to May 11, 2020.
METHODS
We did a whole-population study assessing risks of in-hospital death with COVID-19 between March 1 and May 11, 2020. We included all individuals registered with a general practice in England who were alive on Feb 16, 2020. We used multivariable logistic regression to examine the effect of diabetes status, by type, on in-hospital death with COVID-19, adjusting for demographic factors and cardiovascular comorbidities. Because of the absence of data on total numbers of people infected with COVID-19 during the observation period, we calculated mortality rates for the population as a whole, rather than the population who were infected.
FINDINGS
Of the 61 414 470 individuals who were alive and registered with a general practice on Feb 16, 2020, 263 830 (0·4%) had a recorded diagnosis of type 1 diabetes, 2 864 670 (4·7%) had a diagnosis of type 2 diabetes, 41 750 (0·1%) had other types of diabetes, and 58 244 220 (94·8%) had no diabetes. 23 698 in-hospital COVID-19-related deaths occurred during the study period. A third occurred in people with diabetes: 7434 (31·4%) in people with type 2 diabetes, 364 (1·5%) in those with type 1 diabetes, and 69 (0·3%) in people with other types of diabetes. Unadjusted mortality rates per 100 000 people over the 72-day period were 27 (95% CI 27-28) for those without diabetes, 138 (124-153) for those with type 1 diabetes, and 260 (254-265) for those with type 2 diabetes. Adjusted for age, sex, deprivation, ethnicity, and geographical region, compared with people without diabetes, the odds ratios (ORs) for in-hospital COVID-19-related death were 3·51 (95% CI 3·16-3·90) in people with type 1 diabetes and 2·03 (1·97-2·09) in people with type 2 diabetes. These effects were attenuated to ORs of 2·86 (2·58-3·18) for type 1 diabetes and 1·80 (1·75-1·86) for type 2 diabetes when also adjusted for previous hospital admissions with coronary heart disease, cerebrovascular disease, or heart failure.
INTERPRETATION
The results of this nationwide analysis in England show that type 1 and type 2 diabetes were both independently associated with a significant increased odds of in-hospital death with COVID-19.
FUNDING
None.

Identifiants

pubmed: 32798472
pii: S2213-8587(20)30272-2
doi: 10.1016/S2213-8587(20)30272-2
pmc: PMC7426088
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

813-822

Subventions

Organisme : Medical Research Council
ID : MC_UU_12015/1
Pays : United Kingdom

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Références

Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Diabetes Care. 2018 Mar;41(3):513-521
pubmed: 29330152
Diabetes Care. 2020 Jul;43(7):1399-1407
pubmed: 32409498
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
J Diabetes Sci Technol. 2020 Jul;14(4):813-821
pubmed: 32389027
Lancet Diabetes Endocrinol. 2020 Oct;8(10):823-833
pubmed: 32798471
Diabetes Metab Syndr. 2020 Jul - Aug;14(4):395-403
pubmed: 32334395
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463

Auteurs

Emma Barron (E)

Public Health England, York, UK.

Chirag Bakhai (C)

NHS England and NHS Improvement, London, UK.

Partha Kar (P)

NHS England and NHS Improvement, London, UK; Portsmouth Hospitals NHS Trust, Portsmouth, UK.

Andy Weaver (A)

NHS England and NHS Improvement, London, UK.

Dominique Bradley (D)

NHS England and NHS Improvement, London, UK.

Hassan Ismail (H)

NHS England and NHS Improvement, London, UK.

Peter Knighton (P)

NHS Digital, Leeds, UK.

Naomi Holman (N)

NHS England and NHS Improvement, London, UK; NHS Digital, Leeds, UK; Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK.

Kamlesh Khunti (K)

Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK.

Naveed Sattar (N)

Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK.

Nicholas J Wareham (NJ)

MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

Bob Young (B)

Diabetes UK, London, UK.

Jonathan Valabhji (J)

NHS England and NHS Improvement, London, UK; Department of Diabetes and Endocrinology, St Mary's Hospital, Imperial College Healthcare NHS Trust, London, UK; Division of Diabetes, Endocrinology and Metabolism, Imperial College London, London, UK. Electronic address: jonathan.valabhji@nhs.net.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH